# Sirnaomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sirnaomics

- Industry: Biotechnology
- Headquarters: Gaithersburg, US
- Website: www.sirnaomics.com
- Total disclosed funding: $248M
- Latest round: Series E (Jul 1, 2021)
- Investors on record: 19

## About

Founded in 2008 and based in Maryland, US, Sirnaomics, Inc. is a biopharmaceutical company that develops pharmaceutical medicines for cancer and liver fibrosis. The company was founded by Dr. Patrick Lu, alongside David Evans and George Ji. The company is headquartered in Gaithersburg and has branches in Suzhou, Guangzhou and Hong Kong. In December 2021, Sirnaomics, Inc. closed a pre-IPO funding from new investor Innoforce Pharmaceuticals Co., Ltd.

The company's products are pharmaceutical solutions called STP705 and STP707, a drug that uses RNA interference (RNAi) technology that focuses on the treatment of oncology, liver fibrosis, anti-fibrotic therapeutics, and viral infection. It also uses Polypeptide Nano-Particle (PNP) to protect and deliver the patient's siRNA cargo to the cells.

The company generates revenue by licensing its RNAi delivery technologies, collaborating with pharmaceutical partners on drug development, and advancing clinical candidates toward commercialization.

## Funding rounds

- Series E, Jul 1, 2021, $105M — Rotating Boulder Fund
- Series D, Oct 27, 2020, $96M — Walvax, Sangel Capital, Zhuhai Longmen Capital Management, Riverhead Capital, Shenzhen Hongtao Fund Management, Rotating Boulder Fund, Hongtao Capital, Alpha Win Capital Limited
- Series C, Apr 26, 2019, $22M — CPF, CR Capital, Rotating Boulder Fund, Rich-Yield Capital, Rolling Boulder Investment, Ruiyou Capital, Huarun Zhengda life Science Fund
- Series C, May 18, 2018, $25M — Yuexiu Industrial Investment Funds Management, T-Capital, Sangel Capital, Rotating Boulder Fund, Beijing Huakong Kechuang Investment, Qianhai Shenghui Investment
- Series A, Mar 10, 2008 — Oriza Holdings

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- Yuexiu Industrial Investment Funds Management (https://capitalatlas.ai/funds/yuexiu-industrial-investment-funds-management) — Series C
- T-Capital — Series C
- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Series C, Series D
- Rotating Boulder Fund (https://capitalatlas.ai/funds/rotating-boulder-fund) — Series C, Series D, Series E
- Beijing Huakong Kechuang Investment — Series C
- Qianhai Shenghui Investment — Series C
- CPF — Series C
- CR Capital (https://capitalatlas.ai/funds/cr-capital) — Series C
- Rich-Yield Capital — Series C
- Rolling Boulder Investment — Series C
- Ruiyou Capital — Series C
- Huarun Zhengda life Science Fund — Series C
- Walvax — Series D
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series D
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series D
- Shenzhen Hongtao Fund Management — Series D
- Hongtao Capital — Series D
- Alpha Win Capital Limited — Series D